empagliflozin high dose

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Hypertension

Phase 1

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

CompletedNCT02121483

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2014-06-30End: 2016-02-29Updated: 2016-09-19

Phase 2

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

CompletedNCT02702011

Boehringer IngelheimDiabetes Mellitus, Type 1

Start: 2016-03-20End: 2016-10-03Updated: 2018-04-02

Phase 3

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

CompletedNCT02182830

Boehringer IngelheimDiabetes Mellitus, Type 2, Hypertension

Start: 2014-07-25End: 2017-05-18Updated: 2018-07-31

Related Papers

Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension

Circulation2019-02-2199 citations

The Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth with Type 2 Diabetes

Diabetes2018-06-222 citations

Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.

2018-06-0531 citations

Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.

2018-05-0642 citations

Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus

Current Medical Research and Opinion2017-11-159 citations